ReviewDermatomyositis induced by drug therapy: A review of case reports
Section snippets
Literature search and search terms
The MEDLINE database was searched for literature published from 1950 through the first week of July 2007. Articles were gathered using the Medical Subject Headings term “dermatomyositis,” limited to English language, with the attached subheading “chemically induced.” We searched the resulting articles for case reports. There were 36 articles from this search that included case reports. Then, MEDLINE in-process and other nonindexed citations were searched through July 13, 2007 (which yielded an
Case reports
We identified 50 potentially relevant articles by searching MEDLINE and identified an additional 16 by reviewing the bibliographies of retrieved articles. Of these, 47 articles met inclusion criteria. The total number of case reports in these articles that were included in the analysis was 70. Articles were eliminated for the following reasons: 11 articles did not include a case report but were descriptive instead; 4 articles described cases with cutaneous findings that were of clinical
How may drug-induced DM be diagnosed?
The cutaneous manifestations described in the cases were mostly pathognomonic and/or consistent with DM. The skin pathology was also mostly classic, although skin pathology alone cannot distinguish DM from cutaneous lupus erythematosus.1 To assist with the diagnosis of DM and differentiating it from cutaneous lupus erythematosus, cases may be evaluated for presence of pruritus (more typical in DM than cutaneous lupus erythematosus)1 and proximal muscular weakness. Evaluation of muscular
Conclusions
Drug-induced DM is rare. Hydroxyurea appears to be the most common inciting agent, mostly in the context of treating CML. Patients taking hydroxyurea tend to have late onset (>2 months) of DM, and they lack myositis. The majority of cases of drug-induced DM improve after withdrawal of the medication thought to play a role. If the clinical possibility of drug-induced DM is encountered, drug discontinuation may not only help alleviate DM, but may also serve as a dechallenge test, whereby DM
References (27)
- et al.
Dermatomyositis
Clin Dermatol
(2006) - et al.
Hydroxyurea-induced dermatomyositis-like eruption
J Am Acad Dermatol
(2003) - et al.
Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption
J Am Acad Dermatol
(2003) - et al.
Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea
J Am Acad Dermatol
(1997) - et al.
Hydroxyurea-induced dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea
J Am Acad Dermatol
(1998) - et al.
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
Lancet
(2001) - et al.
Pseudo-dermatomyositis as a complication of hydroxyurea therapy
Clin Exp Rheumatol
(2000) - et al.
Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera
Eur J Dermatol
(2002) - et al.
Dermatomyositis-like eruption following hydroxyurea therapy
J Eur Acad Dermatol Venereol
(2000) - et al.
Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis
Clin Exp Dermatol
(1999)
Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis: viewpoints in dermatology
Clin Exp Dermatol
Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases
Br J Dermatol
Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake
Muscle Nerve
Cited by (62)
Environmental exposures as risk factors for idiopathic inflammatory myopathies
2023, Journal of AutoimmunityJoint and muscle inflammatory disease: A scoping review of the published evidence
2023, Seminars in Arthritis and RheumatismDevelopment of dermatomyositis in patients on biologic therapy: A systematic review
2022, Journal of the American Academy of DermatologySnapshotDx Quiz: September 2021
2021, Journal of Investigative DermatologyDermatomyositis Developed After Exposure to Epstein-Barr Virus Infection and Antibiotics Use
2020, American Journal of the Medical SciencesCitation Excerpt :Drug-induced DM is rare and impossible to predict. Although D-penicillamine, Non-steroidal Anti-inflammatory Drugs and statins are most associated with drug-induced DM, several other medications have been described to induce this phenomenon.2 Epstein-Barr virus (EBV) past exposure as been shown to be positively associated with juvenile dermatomyositis (JDM) in a study.
Cytotoxic Agents
2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
Supported by a generous grant from Ms Joan Fabry.
Disclosure: Dr Seidler received a research/educational grant from Stiefel. Dr Gottlieb (all income paid to employer directly) is a member of the speaker's bureaus of Amgen Inc and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott Labs, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Medacorp, DermiPsor, Can-Fite, and Incyte; and has research/educational grants from Centocor, Amgen, Wyeth, Immune Control, Abbott, Pharmacare, Incyte, Celgene, and Roche.